(Q28444972)

English

NRAS Mutation

genetic variant

MUTATION

In more languages

Statements

transcript variant

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/208

Gain Of Function Variant

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/208

human chromosome 1

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/208

115247090

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/208

115259515

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/208

biological variant of

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/208

positive therapeutic predictor for

trametinib / docetaxel trihydrate combination therapy

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/1225

PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

statement disputed by

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/1227

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

trametinib / metformin combination therapy

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/1230

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/1472

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

determination method

CIViC evidence level D

CIViC 1-star trust rating

medical condition treated

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/1476

Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/1509

MEK targeting in N-RAS mutated metastatic melanoma

ribociclib / binimetinib combination therapy

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/2931

Targeting mutant NRAS signaling pathways in melanoma

determination method

CIViC evidence level B

CIViC 5-star trust rating

medical condition treated

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/2937

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

negative therapeutic predictor for

determination method

CIViC evidence level A

CIViC 4-star trust rating

medical condition treated

colorectal cancer

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/5344

Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

determination method

CIViC evidence level A

CIViC 4-star trust rating

medical condition treated

colorectal cancer

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/5344

Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

colorectal cancer

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/1703

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/6263

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/6263

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

cetuximab / chemotherapy combination therapy

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

colorectal cancer

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/2210

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

negative prognostic predictor for

colorectal cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/27

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/71

NRAS mutation status is an independent prognostic factor in metastatic melanoma

Identifiers

CIViC variant ID

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/208

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28444972&oldid=2014801279"